Firmagon 120 mg/ 80 mg Powder for solution for injection.
PDF Leaflet Revision Date: 03 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of prostate cancer requiring androgen deprivation.
Dosage (summary)
Starting dose: 240 mg (2 x 120 mg s.c.), Maintenance: 80 mg (1 x 80 mg s.c.) monthly.
Onset of Action / Duration
Onset: 3 days, Duration: up to 1 month.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; no indication for use in women.
Key Drug Interactions
- QT prolonging agents
- Class I and III antidysrhythmics
Contraindications
- Hypersensitivity to degarelix
- Pregnancy
- QTc > 450 msec
Common side effects
- Hot flushes
- Weight increase
- Injection site pain
Counselling Points
- Monitor for injection site reactions
- Report any signs of hypersensitivity
- Avoid areas under pressure for injections
Serious warnings
- QT prolongation risk
- Potential for decreased bone density
Important Disclaimer
The Firmagon 120 mg/ 80 mg Powder for solution for injection. professional information leaflet below is the property of Ferring and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
